Protagonist Therapeutics (PTGX) Change in Account Payables (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Change in Account Payables of $3.0 million for Q1 2026, up 142.76% on a YoY basis from $1.2 million in Q1 2025, and up 1078.18% sequentially from -$307000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Change in Account Payables (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Change in Account Payables data on file, last reported at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 142.76% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (up 835.79% YoY), and the FY2025 full-year result was $3.7 million, up 342.16% from the prior year.
- Change in Account Payables advanced to $3.0 million in Q1 2026, from -$307000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $5.6 million in Q1 2022 to a low of -$5.7 million in Q2 2022.
- A 5-year average of $227647.1 and a median of $37000.0 in 2022 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables plunged 7672.97% in 2023 and surged 6110.64% in 2024, its largest moves.
- Tracing PTGX's Change in Account Payables over 5 years: stood at $37000.0 in 2022, then sank by 7672.97% to -$2.8 million in 2023, then jumped by 130.16% to $845000.0 in 2024, then tumbled by 136.33% to -$307000.0 in 2025, then surged by 1078.18% to $3.0 million in 2026.
- Business Quant data shows PTGX's Change in Account Payables at $3.0 million in Q1 2026, -$307000.0 in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | -307,000.00 |
| Dec 31, 2025 | -307,000.00 |
| Sep 30, 2025 | 2.42 Mn |
| Sep 30, 2025 | 2.42 Mn |
| Jun 30, 2025 | 375,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 845,000.00 |
| Dec 31, 2024 | 845,000.00 |
| Sep 30, 2024 | -2.63 Mn |
| Sep 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -198,000.00 |
| Jun 30, 2024 | -198,000.00 |
| Mar 31, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | -2.80 Mn |
| Dec 31, 2023 | -2.80 Mn |